The Filing Desk

BioRestorative Therapies vs Cardiff Oncology

BioRestorative Therapies BRTX · Cardiff Oncology CRDF · Biotechnology

Cardiff Oncology reported revenue of $1 million in fiscal 2025, 1.5 times BioRestorative Therapies' $0 million in fiscal 2025. BioRestorative Therapies' revenue fell 10.3% in its latest year, and Cardiff Oncology's fell 13.2%. BioRestorative Therapies had an operating margin of -4350.1%, against -8256.3% at Cardiff Oncology. Free cash flow was −$11 million at BioRestorative Therapies and −$38 million at Cardiff Oncology.

Side by side

BioRestorative TherapiesCardiff Oncology
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$0M$1M
Revenue growth−10.3%−13.2%
Revenue growth a year, last 5 years32.0%8.4%
Gross margin93.4%—
Operating margin−4,350.1%−8,256.3%
Net margin−3,959.4%−7,732.0%
Free cash flow−$11M−$38M
Free cash flow margin−3,031.7%−6,402.5%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count15.8%40.3%
Last close$1.31$0.89
P/E at the last close——
Insider trades, last 12 months—bought $1.1 million, sold $0
Piotroski F-score—2 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
BioRestorative TherapiesCardiff Oncology
Operating margin
Percent of revenue
BioRestorative TherapiesCardiff Oncology
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
BioRestorative TherapiesCardiff Oncology

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the BioRestorative Therapies and Cardiff Oncology pages.